Foundation Medicine, Inc. (NASDAQ:FMI) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On January 9, 2017, Foundation Medicine, Inc. (the Company)
issued a press release announcing its preliminary financial
results for the quarter and year ended December 31, 2016. A copy
of the press release is being furnished as Exhibit 99.1 to this
Report on Form 8-K.
Item 7.01. Other Events.
Michael Pellini, the Companys Chief Executive Officer, will
present at the 35th Annual J.P. Morgan Healthcare Conference on
Tuesday, January 10, 2017 at 9:00 a.m. PST in San Francisco. The
presentation will be webcast live through the Companys website at
investors.foundationmedicine.com. A copy of the presentation
slide deck is being furnished as Exhibit 99.2 to this Report on
Form 8-K.
Reference is made to, and there is hereby incorporated by
reference into this Item 7.01, the information set forth above
under Item 2.02. Results of Operations and Financial Condition.
relating to the press release announcing preliminary financial
results.
The information in this Report on Form 8-K and Exhibits 99.1 and
99.2 attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
| 99.1 |
Press release issued by Foundation Medicine, Inc. dated January 9, 2017, furnished hereto. |
| 99.2 | Presentation Slide Deck, furnished hereto. |
About Foundation Medicine, Inc. (NASDAQ:FMI)
Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program. Foundation Medicine, Inc. (NASDAQ:FMI) Recent Trading Information
Foundation Medicine, Inc. (NASDAQ:FMI) closed its last trading session up +1.00 at 19.30 with 125,012 shares trading hands.